Search Result

Results for "

NOTA-PSMA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Cathepsin (1) Drug Derivative (1) Integrin (2) Interleukin Related (1) PD-1/PD-L1 (3) PSMA (2) Radionuclide-Drug Conjugates (RDCs) (7) Somatostatin Receptor (3) TREM receptor (1)
By Research Areas:	Cancer (11)

Inhibitors & Agonists

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155483

PSMA-BCH NOTA-PSMA	Radionuclide-Drug Conjugates (RDCs)	Cancer
PSMA-BCH (NOTA-PSMA) is a NOTA-conjugated precursor. NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools .

HY-P10292

NOTA-Pep-1L	Radionuclide-Drug Conjugates (RDCs) Interleukin Related	Cancer
NOTA-Pep-1L specifically targets the IL13RA2 receptor for tumor imaging . NOTA-Pep-1L can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P11347

NOTA-AUNP-12	PD-1/PD-L1	Cancer
NOTA-AUNP-12 is a PD-L1 antagonist (IC₅₀=2.24×10 ⁻⁷ M). NOTA-AUNP-12 is promising for research of cancers (e.g., lung/esophageal cancers) .

HY-175323

NOTA-IMB-RGD	Integrin PD-1/PD-L1	Cancer
NOTA-IMB-RGD is a dual molecular probe targeting integrin αvβ3 and programmed death ligand-1 (PD-L1). NOTA-IMB-RGD blocks the PD-1/PD-L1 signaling pathway and integrin αvβ3-overexpressing tumor vasculature. NOTA-IMB-RGD is promising for research of solid tumors co-expressing PD-L1 and αvβ3 (e.g., glioma, breast cancer) .

HY-P10978

NK224	PD-1/PD-L1	Cancer
NK224 is a peptide-based radiotracer targeting human PD-L1, with dual-radionuclide ( ⁶⁸Ga and ¹⁸F) labeling compatibility enabled by the NOTA chelator. NK224 exhibits high binding affinity to PD-L1, with an IC₅₀ value of 2.45 nM. NK224 visualizes intrapatient tumor heterogeneity and dynamically monitors PD-L1 target occupancy during immunotherapy. NK224 can be used for the study of non-small cell lung cancer (NSCLC) .

HY-P10220

NOTA-COG1410	Radionuclide-Drug Conjugates (RDCs) TREM receptor	Cancer
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting ligand. NOTA-COG1410 is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography (PET/CT). NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P11844

NOTA-FZCD-3	Cathepsin Radionuclide-Drug Conjugates (RDCs)	Cancer
NOTA-FZCD-3 is a NOTA (HY-134418)-labeled FZCD-3 polypeptide precursor that targets cathepsin D (CTSD) with a K_D of 0.65 μM. NOTA-FZCD-3 binds specifically to the active site of CTSD, exhibits rapid in vivo clearance properties, and remains stable in blood for more than 2 h. NOTA-FZCD-3 can be used in studies monitoring CTSD-positive tumors .

HY-P0036D

NOTA-Octreotide	Drug Derivative Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Apoptosis	Cancer
NOTA‑Octreotide is a selective SSTR2‑targeting PET tracer. NOTA‑Octreotide binds specifically to SSTR2 and accumulates in SSTR2‑expressing tissues. NOTA‑Octreotide enables effective imaging of somatostatin receptor‑positive tumors in mice and shows high specific uptake in SSTR2‑expressing organs in healthy rats. NOTA-Octreotide can be used for PET imaging investigation of neuroendocrine tumors. .

HY-P11596

NOTA-Asp2-αvβ6L	Integrin	Cancer
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .

HY-P11488

*JR11-PEG3-DOTA-PSMA-03*	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor PSMA	Cancer
JR11-PEG3-DOTA-PSMA-03 (Compound 2) is an RDC-related compound containing the chelating agent DOTA (HY-W053583), the JR11 peptide (SSTR2 antagonist), and the *PSMA* ligand. JR11-PEG3-DOTA-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC₅₀ s of 94.0 nM, 81.8 nM, respectively. JR11-PEG3-DOTA-PSMA-03 can be radiolabeled with [ ⁶⁸Ga]. [ ⁶⁸Ga] radiolabeled JR11-PEG3-DOTA-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .

HY-P11485

*JR11-PEG3-HBED-CC-PSMA-03*	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor PSMA	Cancer
JR11-PEG3-HBED-CC-PSMA-03 (Compound 1) is an RDC-related compound containing the chelating agent HBED-CC, the JR11 peptide (SSTR2 antagonist), and the *PSMA* ligand. JR11-PEG3-HBED-CC-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC₅₀ s of 59.2 nM, 57.0 nM, respectively. JR11-PEG3-HBED-CC-PSMA-03 can be radiolabeled with [ ⁶⁸Ga]. [ ⁶⁸Ga] radiolabeled JR11-PEG3-HBED-CC-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .

Cat. No.	Product Name	Target	Research Area

HY-P10292

NOTA-Pep-1L	Radionuclide-Drug Conjugates (RDCs) Interleukin Related	Cancer
NOTA-Pep-1L specifically targets the IL13RA2 receptor for tumor imaging . NOTA-Pep-1L can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P11347

NOTA-AUNP-12	PD-1/PD-L1	Cancer
NOTA-AUNP-12 is a PD-L1 antagonist (IC₅₀=2.24×10 ⁻⁷ M). NOTA-AUNP-12 is promising for research of cancers (e.g., lung/esophageal cancers) .

HY-175323

NOTA-IMB-RGD	Integrin PD-1/PD-L1	Cancer
NOTA-IMB-RGD is a dual molecular probe targeting integrin αvβ3 and programmed death ligand-1 (PD-L1). NOTA-IMB-RGD blocks the PD-1/PD-L1 signaling pathway and integrin αvβ3-overexpressing tumor vasculature. NOTA-IMB-RGD is promising for research of solid tumors co-expressing PD-L1 and αvβ3 (e.g., glioma, breast cancer) .

HY-P10978

NK224	PD-1/PD-L1	Cancer
NK224 is a peptide-based radiotracer targeting human PD-L1, with dual-radionuclide ( ⁶⁸Ga and ¹⁸F) labeling compatibility enabled by the NOTA chelator. NK224 exhibits high binding affinity to PD-L1, with an IC₅₀ value of 2.45 nM. NK224 visualizes intrapatient tumor heterogeneity and dynamically monitors PD-L1 target occupancy during immunotherapy. NK224 can be used for the study of non-small cell lung cancer (NSCLC) .

HY-P10220

NOTA-COG1410	Radionuclide-Drug Conjugates (RDCs) TREM receptor	Cancer
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting ligand. NOTA-COG1410 is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography (PET/CT). NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P11844

NOTA-FZCD-3	Cathepsin Radionuclide-Drug Conjugates (RDCs)	Cancer
NOTA-FZCD-3 is a NOTA (HY-134418)-labeled FZCD-3 polypeptide precursor that targets cathepsin D (CTSD) with a K_D of 0.65 μM. NOTA-FZCD-3 binds specifically to the active site of CTSD, exhibits rapid in vivo clearance properties, and remains stable in blood for more than 2 h. NOTA-FZCD-3 can be used in studies monitoring CTSD-positive tumors .

HY-P0036D

NOTA-Octreotide	Drug Derivative Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Apoptosis	Cancer
NOTA‑Octreotide is a selective SSTR2‑targeting PET tracer. NOTA‑Octreotide binds specifically to SSTR2 and accumulates in SSTR2‑expressing tissues. NOTA‑Octreotide enables effective imaging of somatostatin receptor‑positive tumors in mice and shows high specific uptake in SSTR2‑expressing organs in healthy rats. NOTA-Octreotide can be used for PET imaging investigation of neuroendocrine tumors. .

HY-P11596

NOTA-Asp2-αvβ6L	Integrin	Cancer
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .

HY-P11488

*JR11-PEG3-DOTA-PSMA-03*	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor PSMA	Cancer
JR11-PEG3-DOTA-PSMA-03 (Compound 2) is an RDC-related compound containing the chelating agent DOTA (HY-W053583), the JR11 peptide (SSTR2 antagonist), and the *PSMA* ligand. JR11-PEG3-DOTA-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC₅₀ s of 94.0 nM, 81.8 nM, respectively. JR11-PEG3-DOTA-PSMA-03 can be radiolabeled with [ ⁶⁸Ga]. [ ⁶⁸Ga] radiolabeled JR11-PEG3-DOTA-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .

HY-P11485

*JR11-PEG3-HBED-CC-PSMA-03*	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor PSMA	Cancer
JR11-PEG3-HBED-CC-PSMA-03 (Compound 1) is an RDC-related compound containing the chelating agent HBED-CC, the JR11 peptide (SSTR2 antagonist), and the *PSMA* ligand. JR11-PEG3-HBED-CC-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC₅₀ s of 59.2 nM, 57.0 nM, respectively. JR11-PEG3-HBED-CC-PSMA-03 can be radiolabeled with [ ⁶⁸Ga]. [ ⁶⁸Ga] radiolabeled JR11-PEG3-HBED-CC-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.